Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedergsk.com
Press releases
Get the latest updates from Press releases directly as they happen.
Follow now 519 followers
Latest posts
Last updated 7 days ago
Price of world’s first malaria vaccine (RTS,S) for children in endemic countries to be reduced by more than half, to less than $5
7 days ago
Price reduction is commitment by Bharat Biotech made possible through partnership with...
Linerixibat accepted for review by the European Medicines Agency for cholestatic pruritus in patients with primary biliary cholangitis (PBC)
9 days ago
Submission based on data from positive GLISTEN phase III trial
Japan’s Ministry of Health, Labour and Welfare accepts regulatory application to expand use of GSK’s RSV vaccine, Arexvy, in adults aged 18-49 at increased risk of severe RSV disease
12 days ago
If approved, GSK’s RSV vaccine would be the first available in Japan...
GSK’s RSV vaccine, Arexvy, accepted for regulatory review by the European Medicines Agency to expand use in adults 18 years and older
19 days ago
Regulatory decision anticipated H1 2026.
GSK licenses Shigella vaccine candidate to Bharat Biotech for continued development
20 days ago
GSK plc announced today that it has licensed its Shigella vaccine candidate...
Linerixibat New Drug Application (NDA) accepted for review by the US FDA for cholestatic pruritus in patients with primary biliary cholangitis (PBC)
30 days ago
Application based on data from positive GLISTEN phase III trial
GSK data at ASCO and EHA showcase latest research and innovation across the oncology portfolio
about 1 month ago
GSK today announced that data across the oncology pipeline and portfolio will...
PIVOT-PO phase III study for tebipenem HBr stopped early for efficacy following review by Independent Data Monitoring Committee
about 1 month ago
Data to be part of a planned US FDA filing in H2...
Blenrep (belantamab mafodotin) combinations receive positive CHMP opinion in relapsed/refractory multiple myeloma
about 1 month ago
Positive opinion supported by superior efficacy shown in two head-to-head phase III...
Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease (COPD)
about 1 month ago
Approval based on the positive MATINEE and METREX phase III trials
Blenrep (belantamab mafodotin) combinations approved in Japan for treatment of relapsed/refractory multiple myeloma
about 1 month ago
Second major approval for Blenrep combinations, with more expected in 2025
GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD)
about 2 months ago
Affecting up to 5% of the global population, SLD represents an area...